Inspire Medical Systems, Inc. Publishes Inspire V Data at ISSS/AAO-HNS Meetings

Core Insights - Inspire Medical Systems has released clinical outcomes data for its Inspire V system, showcasing its effectiveness for patients with obstructive sleep apnea (OSA) [1][2][3] - The data will be presented at the AAO-HNS and ISSS meetings in Indianapolis, highlighting the system's advancements in safety, efficacy, and patient adherence [1][2] Clinical Data Summary - The Inspire V system trial in Singapore involved 44 patients, showing a 20% reduction in surgical times and a 100% success rate for procedures [2][3] - The primary endpoint, inspiratory phase overlap percentage (IPOP), was 87.1% for Inspire V compared to 79.4% for Inspire IV, indicating superior performance [2] - Patient adherence averaged 5.5±1.7 hours/night, with a significant reduction in the Apnea Hypopnea Index (AHI) from 34.4 events/hour at baseline to 8.3 events/hour at six months [2] Market Release Evaluation - In the U.S., a limited market release involved 101 patients, all of whom successfully used the Inspire therapy with no serious adverse events [3] - At the 60-day check, patients averaged 6.8 hours/night of therapy usage, with a median AHI reduction from 30 to 4.5 events/hour [3] - Surgeons reported an average surgical implant time of 34.5 minutes for Inspire V, with increased implant volume due to shorter procedure times [4] Company Overview - Inspire Medical Systems focuses on innovative, minimally invasive solutions for OSA and is the first company to receive FDA, EU MDR, and PDMA approvals for its neurostimulation technology [8]